Bioelectronics Corp (BIEL)

[Dinofast]

FYI- BioElectronics Analyst Brief: Beyond the Traditional Therapies by Small Cap Traders
Share with LinkedIn


NEW YORK, Oct 20, 2014 /PRNewswire/ -- There can be no doubt that the market for pain relief products will continue to grow, regardless of the economic climate. As the massive baby boomer population ages their aches and pains will follow them and the affordable Care act should make more funding available to spend on pain relief products. As the population becomes more health aware, the use of oral pain medications like aspirin is being questioned and too often topical analgesics don't provide the desired effect. Electronic stimulation of inflamed tissue seems to be a viable alternative that has yet to be fully embraced in the medical community or the general population.

BioElectronics Corporation (OTCBB: BIEL), a development stage company, is engaged in the manufacturing of inexpensive, drug-free, anti-inflammatory medical devices and patches. Its Products include Testimonials, ActiPatch, Allay, Smart Insole and RecoveryRx. The underlying concept of the BIEL product line is to replace the short duration, high power treatments which can only be obtained in the clinic by a trained professional, with an easy to use, self-administered, very low power device that can be used 24 hours per day.

BIEL has good, effective products available, yet the marketplace is inundated with competing electronic pain relief products. The company is working to create brand awareness for their superior products, a process that takes time. Investors willing to take a chance on a development stage company in the burgeoning health care market should be looking at BioElectronics Corp.

An analyst brief which covers a brief technical analysis and analyst recommendation can be viewed in its entirety by using the link below. There is no cost obligation required to view this report: